Archives: Search / 2020 / 2019 / 2018 / 2017 / 2016 / 2015 / 2014 / 2013 / 2012 / 2011
May 6, 2020 Financial and Business Highlights: Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2020 third quarter ended March 31, 2020. "I am incredibly proud of the effort and dedication of all of our... More |
Apr 29, 2020 Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2020 third quarter on Wednesday, May 6, 2020, after the market closes. Lannett management... More |
Apr 8, 2020 Lannett To Meet With FDA Regarding The Clinical Advancement Of Biosimilar Insulin Glargine On June 9 Lannett Company, Inc. (NYSE: LCI) today announced that it is set to meet with the U.S. Food and Drug Administration (FDA) on June 9, 2020 to plan next steps for the clinical advancement of its... More |
Apr 7, 2020 Lannett in the News – Philadelphia Business Journal, April 7, 2020 More |
Mar 31, 2020 --Company Has Launched Five Products in Last Three Months-- Lannett Company, Inc. (NYSE: LCI) today announced that it has commenced marketing a generic version of Adderall XR®, an extended-release mixed salt of a single entity Amphetamine capsule product... More |
Mar 9, 2020 Lannett Company, Inc. (NYSE: LCI) today announced that the company will present at the 32nd Annual ROTH Conference on March 16, 2020 at 2:30 p.m. PT at The Ritz Carlton, in Laguna Niguel,... More |
Feb 5, 2020 Financial and Business Highlights: Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2020 second quarter ended December 31, 2019. "For our fiscal 2020 second quarter, strong sales across multiple... More |
Jan 30, 2020 Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2020 second quarter on Wednesday, February 5, 2020, after the market closes. Lannett... More |
Jan 13, 2020 --Company to Commence Commercial Launch Shortly, Under Brand Name NUMBRINO®-- Lannett Company, Inc. (NYSE: LCI) today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA), submitted under the 505(b)(2) regulatory pathway,... More |
Jan 6, 2020 Lannett Company, Inc. (NYSE: LCI) today announced that it has commenced marketing Venlafaxine Extended Release (ER) Tablets, 150 mg and 225 mg, USP, and Lidocaine Topical Solution 4%. The... More |